Cyclacel Pharmaceuticals Inc. (CYCC) announced Tuesday morning that the independent Data and Safety Monitoring Board of its Phase 3 SEAMLESS study of oral sapacitabine capsules, in acute myeloid leukemia, determined that it would be unlikely for the study to reach statistically significant improvement in survival.
Cyclacel Pharmaceuticals gapped open dramatically lower this morning and is now down 2.06 at $0.77 on the highest volume of the year. The stock has plunged to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.